Login to Your Account

Clinic Roundup

Tuesday, December 28, 2010
Intellect Neurosciences Inc., of New York, reported that a draft pharmacokinetic report from its completed Phase Ib trial for its lead Alzheimer's candidate, OX1, indicated that the drug is rapidly absorbed and distributed in the body after oral administration, the company said, adding that the terminal elimination half-life increased from approximately six to eight hours on the first day of the trial to eight to nine hours on the 14th day.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription